Reiterates 2025 Financial Guidance Following Continued Solid Execution

Highlights

•Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.

•Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively.

•Third quarter 2025 gross margin was 69.9%.

•Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10.3 million.

•Entered a strategic collaboration with SOPHiA GENETICS (Nasdaq: SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) testing solution.

SALT LAKE CITY, November 3, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2025 and reaffirmed its financial guidance on business performance for the full-year 2025.

"I am pleased with our solid results for the quarter, including stable year-over-year revenue performance excluding previously noted headwinds, and 13% year-over-year volume growth for our MyRisk hereditary cancer test. Our disciplined execution also enabled our gross margin to be among the best in the industry and again yielded positive adjusted EBITDA,” said Sam Raha, President and CEO, of Myriad Genetics. “We are executing on our updated strategy to accelerate profitable growth by focusing on the Cancer Care Continuum, including recently entering into a collaboration with SOPHiA GENETICS to provide Pharma customers with CDx development services using a leading liquid biopsy therapy selection assay. We also made changes to our organizational structure and capital deployment, and expect these actions to support us in improving customer experience, gaining market share, and reducing operating expenses as a percentage of revenue going forward."

1 Attributable to UNH discontinuation of coverage (commercial and managed Medicaid) of GeneSight and the divestiture of the European EndoPredict business.

•Test volumes of 386,000 in the third quarter of 2025 increased 3% year-over-year.

•The following table summarizes year-over-year testing volume changes in the company's core product categories:

•The following table summarizes year-over-year revenue changes in the company's core product categories:

•Operating expenses in the third quarter of 2025 were $167.1 million, decreasing $2.7 million year-over-year. Adjusted operating expenses in the third quarter of 2025 decreased $1.0 million year-over-year to $140.0 million, reflecting the company's commitment to disciplined cost management while maintaining investments in key strategic areas.

•Operating loss in the third quarter of 2025 was $23.3 million; adjusted operating income in the third quarter of 2025 was $4.1 million.

Third quarter 2025 cash flow provided by operations was $21.1 million; adjusted operating cash flow in the third quarter of 2025 was $24.8 million. Capital expenditures and capitalization of internal use software costs were $6.2 million in the third quarter 2025. As previously announced, in July 2025, the company entered into a new $200 million term loan facility that replaced its previous asset-based credit facility.

As of the end of the third quarter of 2025, the company had cash and cash equivalents of $145.4 million.

The Oncology business delivered revenue of $81.8 million in the third quarter of 2025.

•Third quarter 2025 hereditary cancer testing revenue in Oncology increased 2% year-over-year while volume increased 9% year-over-year.

•Third quarter 2025 Prolaris testing revenue grew 3% year-over-year. The company continues to make progress and intends to commercially launch its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first half of 2026.

•In September 2025, Myriad Genetics entered a strategic collaboration with SOPHiA GENETICS (Nasdaq: SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory and regulatory affairs capabilities in the United States to support clinical trials, companion diagnostic test development, and FDA registration, and will initially focus on the liquid biopsy application.

•In October 2025, The Lancet Oncology published the results of a study highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). In the study Precise MRD was able to detect ctDNA levels in patients with very low tumor burden. In fact, 94% of patients tested at baseline had ctDNA levels below 100 ppm, which falls in the ultrasensitive testing range.

The Women’s Health business delivered revenue of $85.2 million in the third quarter of 2025.

•Third quarter 2025 hereditary cancer testing revenue and volume for the unaffected population increased 4% and 11% year-over-year, respectively, demonstrating progress with implementing the company's electronic medical records (EMR) solutions and breast cancer risk assessment programs.

•Prenatal testing revenue in the third quarter of 2025 grew 2% year-over-year, reflecting ongoing expansion of payer coverage, particularly for Foresight Expanded Carrier Screen. Prenatal volume over that same period decreased 3% year-over-year largely driven by lower demand for SneakPeek.

•In October 2025, Myriad Genetics added F8 and FXN genes to its Foresight Universal Plus Panel, which now includes all conditions recommended by the American College of Medical Genetics and Genomics for prenatal screening.

GeneSight test revenue was $38.7 million in the third quarter of 2025.

•Third quarter revenue continues to reflect the impact of UnitedHealthcare's discontinuation of coverage of multi-gene panel pharmacogenetic testing, including GeneSight, effective in the first quarter of 2025.

•GeneSight test volume in the third quarter of 2025 grew 8% year-over-year, reflecting ongoing improvement in the year-over-year volume growth reported in the previous quarters of 2025.

•In September 2025, the Journal of Clinical Psychopharmacology published a new meta-analysis of six prospective controlled studies2 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual.

Myriad Genetics does not provide forward-looking guidance in accordance with accounting principles generally accepted in the United States (GAAP) for the measures on which it provides forward-looking non-GAAP guidance as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, real estate optimization and transformation initiatives, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.

Below is a table summarizing Myriad Genetics' full-year 2025 financial guidance*:

These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.

2 Journal of Clinical Psychopharmacology ():10.1097/JCP.0000000000002061, September 3, 2025. | DOI: 10.1097/JCP.0000000000002061 and 1 Pine Rest (Winner et al., 2013), Hamm (Hall-Flavin et al., 2012), La Crosse (Hall-Flavin et al., 2013), GUIDED (Greden et al., 2019), PRIME Care (Oslin et al., 2022), GAPP-MDD (Tiwari et al., 2022)

A conference call will be held today, Monday, November 3, 2025, at 4:30 p.m. ET to discuss Myriad Genetics’ financial results and business developments for the third quarter 2025. A live webcast of the conference call can be accessed on Myriad Genetics' Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register at https://register-conf.media-server.com/register/BI0b8f183f8c424418a8f2161c86345c34. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at investor.myriad.com.

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, myChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Foresight Universal Plus, Precise Tumor, Precise Oncology Solutions, Precise Liquid, Precise MRD, FirstGene, SneakPeek, SneakPeek Early Gender DNA Test, SneakPeek Snap, Urosuite, Mygenehistory, Health.Illuminated., RiskScore, Prolaris, and GeneSight are registered trademarks or trademarks of Myriad Genetics, Inc. All third-party marks—® and ™—are the property of their respective owners. © 2025 Myriad Genetics, Inc. All rights reserved.

WH = Women’s Health

ONC = Oncology

PGx = Pharmacogenomics

Hereditary Cancer – MyRisk, BRACAnalysis, BRACAnalysis CDx

Tumor Profiling – myChoice CDx, Prolaris, Precise Tumor, EndoPredict

Prenatal – Foresight, Prequel, SneakPeek Condensed Consolidated Statements of Operations (unaudited)

Pharmacogenomics – GeneSight

Condensed Consolidated Balance Sheets (unaudited)

			September 30, 2025						December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents			$	145.4					$	102.4
Trade accounts receivable			118.0						121.2
Inventory			31.6						27.5
Prepaid taxes			13.8						16.4
Prepaid expenses and other current assets			36.0						30.5
Total current assets			344.8						298.0
Operating lease right-of-use assets			50.6						55.0
Property, plant and equipment, net			111.4						117.4
Intangibles, net			163.1						262.4
Goodwill			51.6						286.3
Other assets			6.6						8.5
Total assets			$	728.1					$	1,027.6
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable			$	31.8					$	32.3
Accrued liabilities			108.3						119.0
Current maturities of operating lease liabilities			7.9						12.8
Total current liabilities			148.0						164.1
Unrecognized tax benefits			1.2						32.7
Long-term debt			119.5						39.6
Noncurrent operating lease liabilities			84.9						87.9
Other long-term liabilities			1.7						2.2
Total liabilities			355.3						326.5
Commitments and contingencies
Stockholders’ equity:
Common stock, 93.1 and 91.3 shares outstanding at September 30, 2025 and December 31, 2024, respectively			0.9						0.9
Additional paid-in capital			1,486.8						1,457.8
Accumulated other comprehensive loss			(0.1)						(0.8)
Accumulated deficit			(1,114.8)						(756.8)
Total stockholders' equity			372.8						701.1
Total liabilities and stockholders’ equity			$	728.1					$	1,027.6

Condensed Consolidated Statements of Cash Flows (unaudited)

(in millions)

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including (i) the company's full-year 2025 financial guidance, (ii) the company's execution of its updated strategy to accelerate profitable growth by focusing on the Cancer Care Continuum, including its collaboration with SOPHiA GENETICS to provide Pharma customers with CDx development services using a leading liquid biopsy therapy selection assay, (iii) the view that recent changes to the company's organizational structure and capital deployment will support the company in improving customer experience, gaining market share, and reducing operating expenses as a percentage of revenue going forward, (iv) the company's intention to commercially launch its first AI-driven prostate cancer test, in partnership with PATHOMIQ, in the first half 2026, and (v) that the company's partnership with SOPHiA GENETICS will leverage its advanced laboratory and regulatory affairs capabilities in the United States to support clinical trials, companion diagnostic test development, and FDA registration. These “forward-looking statements” are management’s present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.

These risks include, but are not limited to: the risk that sales and profit margins of the company’s existing tests may decline; the risk that the company may not be able to operate its business on a profitable basis; risks related to the company’s ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to recent changes in the company's senior management team and the successful implantation of the company's strategic plan; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for the company’s tests or the company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests, including with respect to UNH's coverage decisions not to provide coverage for certain multi-gene panel pharmacogenetic tests, including the company's GeneSight test; risks related to increased competition and the development of new competing tests; the risk that the company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; the risk that the company is not able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if it all; the risk that the company may not successfully develop new markets or channels for its tests; the risk that licenses to the technology underlying the company’s tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the company’s laboratory testing facilities; risks related to public concern over genetic testing in general or the company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the company’s ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the company’s ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires or develops; risks related to the company’s projections or estimates about the potential market opportunity for the company’s current and future products; the risk that the company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the company’s tests; the risk of patent-infringement claims or challenges to the validity of the company’s patents; risks related to changes in intellectual property laws covering the company’s tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks and other cybersecurity incidents; risks of new, changing and competitive technologies in the United States and internationally and that the company may not be able to keep pace with the rapid technology changes in its industry, or properly leverage new technologies to achieve or sustain competitive advantages in its products; the risk that the company may be unable to comply with financial or operating covenants under the company’s credit or lending agreements; the risk that the company may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting; risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of the company's insurance coverage limits and scope of insurance coverage with respect thereto; and other factors discussed under the heading “Risk Factors” contained in Part I, Item 1A of the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad Genetics is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Statement regarding use of non-GAAP financial measures

In this press release, the company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the company’s business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of each schedule.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

The company does not forecast GAAP operating expenses, net income (loss) or earnings per share because it cannot predict certain elements that are included in reported GAAP results. Please see above under “Financial Guidance” for a full explanation.